Medical Treatment of Osteoporosis.
10.5124/jkma.2004.47.9.889
- Author:
Dong Won BYUN
1
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon Hospital, Korea. byundw@schbc.ac.kr
- Publication Type:Original Article
- Keywords:
Osteoporosis;
Treatment;
Side effect
- MeSH:
Alendronate;
Calcitonin;
Estrogens;
Female;
Fluorides;
Humans;
Metabolism;
Osteogenesis;
Osteoporosis*;
Parathyroid Hormone;
Raloxifene Hydrochloride;
Risedronate Sodium;
Strontium
- From:Journal of the Korean Medical Association
2004;47(9):889-894
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Osteoporosis is a common and significant health problem in more than 1/3 of postmenopausal women. Strategies for the medical treatment of osteoporosis are primarily based on decreasing the resorption component of bone turnover by estrogen, alendronate, risedronate, raloxifene, or calcitonine. Recently there are therapies that are focused on increasing bone formation by fluoride, parathyroid hormone, or strontium ranelate. This article reviews the medical treatment of osteoporosis focusing on the pharmacokinetic effects on the bone metabolism, anti-fracture effects, usage of the drugs and their side effects.
